Nepicastat oralAlternative Names: DBH inhibitor programme; DβH inhibitor programme; Nepicastat hydrochloride; SYN-117
Latest Information Update: 02 Mar 2017
$50 / €47 *
At a glance
- Originator Roche
- Developer Biotie Therapies Corp.
- Class Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Imidazoles; Neuropsychotherapeutics; Small molecules; Thiones
- Mechanism of Action Dopamine beta hydroxylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cocaine abuse; Parkinson's disease; Post-traumatic stress disorders